Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
826 stopped studies mapped to Malignant Female Reproductive System Neoplasm and descendants · 86% state a reason
Over the 826 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04498520 | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic… | Phase 1 | withdrawn | Aug 4, 2020 | Pamela Munster | Funding | Funding |
| NCT02055690 | PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent…(PAZOFOS) | Phase 1 / Phase 2 | terminated | Feb 5, 2014 | The Christie NHS Foundation Trust | Safety | Safety / toxicity |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in… | Phase 1 / Phase 2 | withdrawn | Jul 9, 2020 | NKGen Biotech, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT03658109 | Lidocaine Infusion or Quadratus Lumborum Block and Intrathecal Morphine, Versus… | Early Phase 1 | terminated | Sep 5, 2018 | University of Alabama at Birmingham | Recruitment challenges due to COVID-19 | COVID-19 / pandemic |
| NCT01016561 | Magnetic Resonance Imaging-Based Radiation Therapy and Cisplatin in Patients With Stage… | N/A | terminated | Nov 19, 2009 | Abramson Cancer Center at Penn Medicine | Poor accrual/enrollments | Enrollment / accrual |
| NCT03029585 | Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer | Phase 2 | terminated | Jan 24, 2017 | NanOlogy, LLC | Business reasons | Sponsor / business decision |
| NCT03902379 | Web-Based Coping and Communication Skills Intervention in Improving Psychological… | N/A | withdrawn | Apr 4, 2019 | Rutgers, The State University of New Jersey | The study was never initiated, no patients were enrolled. It has been closed with the IRB. | Enrollment / accrual |
| NCT04239014 | A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment…(DUETTE) | Phase 2 | withdrawn | Jan 23, 2020 | AstraZeneca | Sponsor made the decision to terminate the DUETTE study based on the interim analysis of the… | Efficacy / futility |
| NCT03134638 | A Study of SY-1365 in Adult Patients With Advanced Solid Tumors | Phase 1 | terminated | May 1, 2017 | Syros Pharmaceuticals | Business Decision | Sponsor / business decision |
| NCT03572478 | Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer | Phase 1 / Phase 2 | terminated | Jun 28, 2018 | University of Chicago | The study was terminated due to lack of efficacy. | Efficacy / futility |
| NCT01334047 | Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients | Phase 1 / Phase 2 | terminated | Apr 12, 2011 | Steinar Aamdal | The study needed to be terminated due to new knowledge about cancer vaccines. A new protocol with… | Other (stated, no rule matched) |
| NCT03146663 | NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer | Phase 2 | terminated | May 10, 2017 | NuCana plc | Despite promising efficacy and a good tolerability profile in Part I, it was decided not to… | Efficacy / futility |
| NCT03622931 | Patients With Relapsed Ovarian Cancer (2nd and 3rd Line) Treated With Chemotherapy…(TRACEII) | Phase 2 | terminated | Aug 9, 2018 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | due to lack of recruitment | Enrollment / accrual |
| NCT00285415 | A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed… | Phase 2 | terminated | Feb 2, 2006 | Carilion Clinic | Investigator abruptly left Carilion. | Investigator |
| NCT03162562 | The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in… | Phase 1 | terminated | May 22, 2017 | CanariaBio Inc. | Sponsor Decision to discontinue long-term follow-up | Sponsor / business decision |
| NCT03042897 | Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I… | N/A | withdrawn | Feb 3, 2017 | University of Southern California | PI left institution | Investigator |
| NCT02947152 | HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma | Phase 1 | terminated | Oct 27, 2016 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT01097239 | Examining the Role of Transrectal High Intensity Focused Ultrasound (HIFU) in Rectal… | Phase 1 / Phase 2 | withdrawn | Apr 1, 2010 | Imperial College London | Failure to recruit. | Enrollment / accrual |
| NCT00506779 | Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma | Phase 1 / Phase 2 | terminated | Jul 25, 2007 | M.D. Anderson Cancer Center | the study was terminated early due to poor enrollment | Enrollment / accrual |
| NCT01511055 | Intra-op Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific… | Phase 2 | terminated | Jan 18, 2012 | Mayo Clinic | Accrual temporarily suspended, followed by study closure due to technical problems with… | Enrollment / accrual |
| NCT03312114 | Anti-PD-L1 and SAbR for Ovarian Cancer | Phase 2 | terminated | Oct 17, 2017 | University of Texas Southwestern Medical Center | low accrual | Enrollment / accrual |
| NCT03292172 | A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and… | Phase 1 | terminated | Sep 25, 2017 | Hoffmann-La Roche | Portfolio prioritization | Sponsor / business decision |
| NCT04197219 | Pembrolizumab With Axitinib in Recurrent Endometrial Cancer | Phase 2 | withdrawn | Dec 13, 2019 | Case Comprehensive Cancer Center | PI is leaving institution | Other (stated, no rule matched) |
| NCT00503581 | Megestrol in Treating Patients With Endometrial Neoplasia or Endometrial Hyperplasia | Phase 2 | terminated | Jul 19, 2007 | Gynecologic Oncology Group | not stated | Not stated |
| NCT03423082 | Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical… | Phase 4 | terminated | Feb 6, 2018 | Nghi Nguyen | Limited subject enrollment | Enrollment / accrual |
| NCT04567095 | A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization… | — | withdrawn | Sep 28, 2020 | Allergan | This study was cancelled before any data collection due to business reasons. | Sponsor / business decision |
| NCT04567589 | A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization… | — | withdrawn | Sep 28, 2020 | Allergan | This study was cancelled before any data collection due to business reasons. | Sponsor / business decision |
| NCT02425878 | Ulipristal Acetate 10 mg and Asisted Reproduction | Phase 3 | terminated | Apr 24, 2015 | Instituto Valenciano de Infertilidad, IVI VALENCIA | Lack of availibility of eligible subjects | Other (stated, no rule matched) |
| NCT03203993 | China Ovarian Cancer BRCA Testing Study(CRONUS) | — | terminated | Jun 29, 2017 | AstraZeneca | Failure to obtain HGR approval. | Other (stated, no rule matched) |
| NCT02476955 | Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole | Phase 1 | terminated | Jun 22, 2015 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | not stated | Not stated |
| NCT01690468 | PTX-200 and Carboplatin in Ovarian Cancer | Phase 1 / Phase 2 | terminated | Sep 21, 2012 | Prescient Therapeutics, Ltd. | Enrollment stopped prior to Phase 1b, change in strategic focus | Enrollment / accrual |
| NCT03957096 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | Phase 1 | terminated | May 21, 2019 | Seagen Inc. | Sponsor decision based on portfolio prioritization | Sponsor / business decision |
| NCT01535157 | Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer | Phase 1 / Phase 2 | terminated | Feb 17, 2012 | South Plains Oncology Consortium | drug combination not providing any efficacy. Will use this data in opening new trial | Efficacy / futility |
| NCT01939028 | Lymph Node Mapping in Patients With Newly Diagnosed Endometrial Cancer Undergoing Surgery | N/A | terminated | Sep 11, 2013 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT02346955 | Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in… | Phase 1 | terminated | Jan 27, 2015 | Famewave Ltd. | not stated | Not stated |
| NCT02045433 | Stereotactic Body Radiation Therapy (SABR) for Definitive Treatment of Locally Advanced… | Phase 2 | terminated | Jan 24, 2014 | University of Texas Southwestern Medical Center | The study was prematurely closed due to unacceptable toxicity. | Safety / toxicity |
| NCT02326844 | BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2… | Phase 2 | terminated | Dec 30, 2014 | National Cancer Institute (NCI) | Study was closed by the Cancer Therapy Evaluation Program (CTEP) | Other (stated, no rule matched) |
| NCT01280045 | Influence of Aromatase Inhibitors and GnRH Analogs to Treat Uterine Leiomyoma by Vaginal… | N/A | terminated | Jan 20, 2011 | University of Sao Paulo | No grant was received then we stopped the recruitment | Enrollment / accrual |
| NCT01738724 | Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared… | Phase 4 | terminated | Nov 30, 2012 | University of Sao Paulo | PI went for a post-doc course and when he came back he moved for another job | Other (stated, no rule matched) |
| NCT03115593 | Compare the Performance of Targeted Biopsy Versus Aspiration Biopsy With a Pipette for… | N/A | withdrawn | Apr 14, 2017 | Brugmann University Hospital | Lack of human ressources | Other (stated, no rule matched) |
| NCT03587129 | Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer | Phase 2 | terminated | Jul 16, 2018 | First Affiliated Hospital of Harbin Medical University | No patient enter this study. | Other (stated, no rule matched) |
| NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors… | Phase 1 | terminated | Nov 29, 2010 | AIDS Malignancy Consortium | Inadequate accrual rate | Enrollment / accrual |
| NCT02718417 | Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN… | Phase 3 | terminated | Mar 24, 2016 | Pfizer | The study was terminated based on the results of a planned interim analysis that showed futility of… | Efficacy / futility |
| NCT02387125 | Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or… | Phase 1 | terminated | Mar 12, 2015 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | This study did not meet the efficacy objective | Efficacy / futility |
| NCT03583736 | Rapid First Contact Using Virtual Visits to Improve Time-To-Treatment for Uterine Cancer | N/A | withdrawn | Jul 11, 2018 | Case Comprehensive Cancer Center | PI decision | Other (stated, no rule matched) |
| NCT00753740 | Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients. | Phase 2 | withdrawn | Sep 16, 2008 | NewLink Genetics Corporation | Poor trial recruitment | Enrollment / accrual |
| NCT02317302 | FDG Tumor Heterogeneity During Chemoradiation as a Predictor of Response in Patients With… | Phase 1 | terminated | Dec 16, 2014 | Washington University School of Medicine | Insufficient funding | Funding |
| NCT03318107 | Ultrasound and Photoacoustic Imaging for Cervical Cancer | N/A | terminated | Oct 23, 2017 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT02441140 | Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by Culdocentesis | N/A | terminated | May 12, 2015 | Dana-Farber Cancer Institute | Poor accrual | Enrollment / accrual |
| NCT01533207 | Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or… | Phase 3 | terminated | Feb 15, 2012 | Gynecologic Oncology Group | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated May 18, 2021source: clinicaltrials